Hemiretinal Vein Occlusion — A Unique Entity That Responds Well to Treatment
Hemiretinal vein occlusion (HRVO) affects roughly half the retina, but has historically been lumped in with either branch or central RVO in clinical trials — potentially skewing the results of both. Dr Adrian Hunt's co-authored research used Fight Retinal Blindness! registry data to demonstrate that HRVO is a unique entity with its own distinct treatment profile, and that it responds particularly well to anti-VEGF therapy.
The paper was published in the British Journal of Ophthalmology in 2022. Related RVO findings were presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in 2021 — the largest gathering of eye and vision researchers in the world. The HRVO publication was subsequently featured by Review of Optometry and Ophthalmology Advisor in the United States.
What this means for patients: Patients diagnosed with hemiretinal vein occlusion can be reassured that their condition responds particularly well to injection treatment. Recognising HRVO as its own entity — rather than grouping it with branch or central RVO — means treatment expectations and outcomes are specific to the condition they actually have.